Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
BeiGene (ONC)
NASDAQ:ONC
ONC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$126.97 - $248.16
Previous CloseN/A
VolumeN/A
Average Volume (3M)354.46K
Market Cap
$27.08B
Enterprise Value$22.17B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.49
Next Earnings
Feb 27, 2025EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.24
Shares Outstanding97,859,010
10 Day Avg. Volume381,962
30 Day Avg. Volume354,459
Standard Deviation0.13
R-Squared0.06
Alpha0.00759
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.65
Price to Cash Flow (P/CF)33.70
P/FCF Ratio87.70
Enterprise Value/Market Cap0.82
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.66
Enterprise Value/Ebitda-30.35
Forecast
1Y Price Target
$258.09Price Target Upside5.69% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Bulls Say, Bears Say
Bulls Say
Financial PerformanceBeOne achieved a milestone by generating operating cash inflows of US$188mn during 3Q24, being the first time for the Company to report positive quarterly operating cash flow.
Market PerformanceGlobal sales of zanubrutinib reached US$690mn in 3Q24, with its share in the global BTKi market increasing to ~25%, indicating strong market performance.
Product DevelopmentBeOne introduced 13 new molecules into clinic in 2024, showing a strong potential for future growth in its early-stage pipeline.
Bears Say
Market CompetitionThe company faces fierce competition in the BTK inhibitor market in China.
Safety ConcernsBGNE's CDK4 inhibitor may have safety advantages over PFE's atirmociclib, showcasing lower levels of hematologic toxicity.
Sales DeclineThe sales of the self-developed drug pamiparib decreased by 48.3% year-on-year.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
ONC FAQ
What was BeiGene’s price range in the past 12 months?
BeiGene lowest stock price was $126.97 and its highest was $248.16 in the past 12 months.
What is BeiGene’s market cap?
BeiGene’s market cap is $27.08B.
When is BeiGene’s upcoming earnings report date?
BeiGene’s upcoming earnings report date is Feb 27, 2025 which is in 6 days.
How were BeiGene’s earnings last quarter?
BeiGene released its earnings results on Nov 12, 2024. The company reported -$1.15 earnings per share for the quarter, missing the consensus estimate of -$1.114 by -$0.036.
Is BeiGene overvalued?
According to Wall Street analysts BeiGene’s price is currently Undervalued.
Does BeiGene pay dividends?
BeiGene does not currently pay dividends.
What is BeiGene’s EPS estimate?
BeiGene’s EPS estimate is -1.02.
How many shares outstanding does BeiGene have?
BeiGene has 97,859,010 shares outstanding.
What happened to BeiGene’s price movement after its last earnings report?
BeiGene reported an EPS of -$1.15 in its last earnings report, missing expectations of -$1.114. Following the earnings report the stock price went down -5.56%.
Which hedge fund is a major shareholder of BeiGene?
Currently, no hedge funds are holding shares in ONC
---
BeiGene Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$258.09 (5.69% Upside)
$258.09 (5.69% Upside)
Blogger Sentiment
Bullish
ONC Sentiment 100%
Sector Average 71%
Sector Average 71%
Insider Transactions
Sold Shares
Worth $3.8B over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 3.4%
Last 30 Days ▼ 10.8%
Last 30 Days ▼ 10.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
59.67%
12-Months-Change
Fundamentals
Return on Equity
-25.04%
Trailing 12-Months
Asset Growth
5.54%
Trailing 12-Months
Company Description
BeiGene
BeiGene, Ltd.is a biopharmaceutical company. The company primarily focuses on developing molecularly targeted and immuno-oncology drugs for the treatment of cancer.
---
ONC Stock 12 Month Forecast
Average Price Target
$258.09
▲(5.69% Upside)
Technical Analysis
Best Analysts Covering ONC
1 Year
1 Year Success Rate
12/13 ratings generated profit
1 Year Average Return
+15.96%
reiterated a buy rating 27 days ago
Copying Kelly Shi's trades and holding each position for 1 Year would result in 92.31% of your transactions generating a profit, with an average return of +15.96% per trade.
---